A Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A Inhalation Solution in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Double Lung Transplant



Status:Recruiting
Conditions:Bronchitis, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:3/31/2019
Start Date:March 2019
End Date:October 2021
Contact:Tammy Abuan, RN, MS
Email:t.abuan@breath-therapeutics.com
Phone:+1.650.272.0655

Use our guide to learn which trials are right for you!

A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow® Device Plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Double Lung Transplantation

This is a Phase III randomized, controlled clinical trial of L-CsA for the treatment of
bronchiolitis obliterans syndrome in adults diagnosed with BOS following double lung
transplant. Patients will receive either L-CsA (10 mg) via the PARI Investigational eFlow®
Device twice daily plus Standard of Care (SoC) treatment, or SoC alone, for a period of 48
weeks. All patients will be eligible to continue in an open-label extension trial of L-CsA
following completion of BOSTON-2.

Regardless of treatment allocation, all patients will continue to receive their SoC regimen
for maintenance of the lung allograft. Eligible patients for the clinical trial must have a
tacrolimus-based triple-drug therapy in combination with mycophenolate mofetil or its
equivalent and a corticosteroid.

A total of 11 visits will be performed during the clinical trial. After informed consent has
been obtained, a Screening Visit will be carried out in order to check general eligibility
for participation. At the Randomization Visit, inclusion and exclusion criteria will be
re-checked and spirometry performed. During the 48-week treatment period, visits are
scheduled every 4-8 weeks. If a patient has an event that meets one of the criteria for
progression of BOS, he/she will return to the clinic within 2-weeks for an unscheduled visit
to have spirometry and other procedures performed.

Inclusion Criteria:

1. Adult patients of ≥ 18 years.

2. Patients with diagnosis of BOS Grade 0-p with screening FEV1 between 85-81% of
personal best FEV1 value post-transplant plus risk factors as defined below, OR BOS
Grade 1 with screening FEV1 between 80-66% of personal best FEV1 value
post-transplant. Patients with diagnosis of BOS Grade 0-p must have >/=2 of these risk
factors for BOS:

- Primary graft dysfunction (PGD)

- Acute cellular rejection

- Lymphocytic bronchiolitis

- Humoral rejection (e.g. de novo anti-human leukocyte antigen antibodies)

- Gastro-oesophageal reflux and microaspiration

- Infection (Viral, Bacterial, Fungal)

- Persistent neutrophil influx and sequestration (bronchoalveolar lavage
neutrophilia)

- Autoimmunity (collagen V sensitization)

3. Patients with an FEV1/FVC ratio of < 0.8.

4. Patients in whom the diagnosis of BOS has been confirmed by the elimination of other
possible causes of obstructive lung disease.

5. Patients with a diagnosis of BOS 0-p or BOS 1 made at least 1 year after transplant
surgery and within 6 months prior to the Screening Visit.

6. Patients receiving a tacrolimus-based basic immunosuppression regimen in combination
with MMF (or equivalent) and corticosteroids. This basic immunosuppression regimen
must be stable (without changes to doses) for at least 4-weeks prior to Randomization.

7. Patients must consent to retrieve prespecified data from the historic medical record
(e.g., information related to the transplant surgery; spirometry data; medication
use).

8. Patients must be receiving prophylaxis against Cytomegalovirus (CMV) and Pneumocystis
pneumonia.

9. Patients capable of understanding the purposes and risks of the clinical trial, who
have given written informed consent and agree to comply with the clinical trial
requirements/visit schedules, and who are capable of aerosol inhalation.

10. Women of childbearing potential must have a negative serum pregnancy test within 7
days prior to randomization and must agree to use one of the methods of contraception
listed in Appendix II of the protocol for their duration of clinical trial
participation.

11. Patients have no concomitant diagnoses that are considered fatal wtihin one year (12
months).

Exclusion Criteria:

1. Patients with confirmed other causes for loss of lung function, such as infection,
acute rejection, restrictive allograft syndrome (RAS), etc.

2. Patients with Cystic Fibrosis.

3. Patients with donor-specific antibody (DSA) positivity at the Screening Visit.

4. Active bacterial, viral, or fungal infection not successfully resolved at least 4
weeks prior to the Screening Visit.

5. Mechanical ventilation within 12 weeks prior to Randomization.

6. Patient has baseline resting oxygen saturation of < 89% on room air or use of
supplemental oxygen.

7. History or presence of bronchial strictures or airway stents or airways requiring
balloon dilatations to maintain patency.

8. Known hypersensitivity to L-CsA or to cyclosporine A.

9. Patients with chronic renal failure, defined as serum creatinine > 2.5 mg/ dL, or
requiring chronic dialysis.

10. Patients with liver disease and serum bilirubin > 3-fold upper normal value or
transaminases > 2.5 upper normal value.

11. Patients with a history of malignancy, including post-transplant lymphoproliferative
disorder, with the exception of treated, localized basal and squamous cell carcinomas.

12. Pregnant women or women who are unwilling to use appropriate birth control to avoid
pregnancy over the course of the clinical trial.

13. Women who are currently breastfeeding.

14. Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to
the Screening Visit. This is defined as any treatment that is implemented under an
Investigational New Drug (IND) or compassionate use.

15. Patients who have received extracorporeal photophoresis (ECP) for treatment of BOS
within 2 months prior to Randomization.

16. Patients who are currently participating in an interventional clinical trial.

17. Psychiatric disorders or altered mental status precluding understanding of the
informed consent process and/or completion of the necessary procedures.

18. Any co-existing medical condition that in the Investigator's judgment will
substantially increase the risk associated with the patient's participation in the
clinical trial.
We found this trial at
20
sites
Phoenix, Arizona 85013
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
3500 Gaston Avenue
Dallas, Texas 75246
1.800.422.9567
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
425 University Blvd.
Indianapolis, Indiana 46202
(317) 274-4591
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Baltimore, Maryland 20742
(301) 405-1000
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Baltimore, Maryland 21287
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Falls Church, Virginia 22042
?
mi
from
Falls Church, VA
Click here to add this to my saved trials
6550 Fannin St
Houston, Texas 77030
(713) 790-3311
Houston Methodist Hospital Houston Methodist is comprised of a leading academic medical center in the...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
757 Westwood Plaza
Los Angeles, California 90024
(310) 825-9111
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94305
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3401 N Broad St
Philadelphia, Pennsylvania
(215) 707-2000
Temple University Hospital On January 18, 1892 a three-story house at 3403 North Broad Street...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
50 Beale Street
San Francisco, California 94121
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Vienna,
Click here to add this to my saved trials